Shots:

• Mozart highlighted pre-clinical results of KIR x ICOS bispecific Ab targeting CD8 regulatory T cells at Immunology 2024 under the title, ‘Pre-clinical Pharmacology and Tolerability Characterization of a Novel KIR x ICOS Targeting Bispecific CD8 Treg Modulator’
• The data demonstrated restoration of CD8 Treg function by binding inhibitory receptor KIR & costimulatory receptor ICOS along with activating & increasing CD8 Treg’s frequency & ability to destroy pathogenic CD4 T cells in a dose-dependent manner   
• It further increased the ICOS signaling in CD8 Treg cells, improved survival in a highly inflammatory disease model by decreasing proinflammatory cytokines & showed favorable tolerability in humanized mice

Ref: Mozart Therapeutics | Image: Mozart Therapeutics

Related News:- Krystal Biotech doses First Patient with Inhaled KB707 in the P-I study for treating Locally Advanced or Metastatic Solid Tumors of the Lung

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com